These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7793865)

  • 1. French multicenter study involving eight test sites for radiometric determination of activities of 10 antimicrobial agents against Mycobacterium avium complex.
    Rastogi N; Bauriaud RM; Bourgoin A; Carbonnelle B; Chippaux C; Gevaudan MJ; Goh KS; Moinard D; Roos P
    Antimicrob Agents Chemother; 1995 Mar; 39(3):638-44. PubMed ID: 7793865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method.
    Tomioka H; Saito H; Fujii K; Sato K; Hidaka T
    Antimicrob Agents Chemother; 1993 Jan; 37(1):67-70. PubMed ID: 8431020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
    Huang CC; Wu MF; Chen HC; Huang WC
    J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium.
    Fattorini L; Li B; Piersimoni C; Tortoli E; Xiao Y; Santoro C; Ricci ML; Orefici G
    Antimicrob Agents Chemother; 1995 Mar; 39(3):680-5. PubMed ID: 7793873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.
    Lin S; Hua W; Wang S; Zhang Y; Chen X; Liu H; Shao L; Chen J; Zhang W
    BMC Microbiol; 2022 Jul; 22(1):175. PubMed ID: 35804298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin.
    Yajko DM; Sanders CA; Nassos PS; Hadley WK
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2442-4. PubMed ID: 2088204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
    Rastogi N; Goh KS; Bryskier A; Devallois A
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2483-7. PubMed ID: 8913450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.
    Rastogi N; Goh KS; Bryskier A
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1433-8. PubMed ID: 8092850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of clarithromycin alone or in combination with other antimicrobial agents against Mycobacterium avium-intracellulare. Complex strains isolated from AIDS patients.
    Mascellino MT; Iona E; Fattorini L; De Gregoris P; Hu CQ; Santoro C; Orefici G
    J Chemother; 1991 Dec; 3(6):357-62. PubMed ID: 1840274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference in drug susceptibility distribution and clinical characteristics between
    Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
    J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical features of patients with bacteraemia caused by Mycobacterium avium complex species and antimicrobial susceptibility of the isolates at a medical centre in Taiwan, 2008-2014.
    Lee MR; Chien JY; Huang YT; Liao CH; Shu CC; Yu CJ; Hsueh PR
    Int J Antimicrob Agents; 2017 Jul; 50(1):35-40. PubMed ID: 28478210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to various drugs].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1991 Jul; 66(7):489-92. PubMed ID: 1890791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
    Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
    J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex.
    Hoffner SE; Kratz M; Olsson-Liljequist B; Svenson SB; Källenius G
    J Antimicrob Chemother; 1989 Sep; 24(3):317-24. PubMed ID: 2808189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex.
    Piersimoni C; Tortoli E; Mascellino MT; Passerini Tosi C; Sbaraglia G; Mandler F; Bistoni F; Bornigia S; De Sio G; Goglio A
    J Antimicrob Chemother; 1995 Sep; 36(3):497-502. PubMed ID: 8830013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ESP culture system for drug susceptibilities of Mycobacterium avium complex.
    Lui AY; Labombardi VJ; Turett GS; Kislak JW; Nord JA
    Clin Microbiol Infect; 2000 Dec; 6(12):649-52. PubMed ID: 11284923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China.
    Zhao X; Wang Y; Pang Y
    Infect Genet Evol; 2014 Oct; 27():332-8. PubMed ID: 25131955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages.
    Pellegrin I; Maugein J; Lapeyre C; Barbeau P; Leng B; Pellegrin JL
    J Antimicrob Chemother; 1996 Mar; 37(3):501-10. PubMed ID: 9182107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.
    Peloquin CA
    Clin Pharmacokinet; 1997 Feb; 32(2):132-44. PubMed ID: 9068928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
    Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
    J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.